Lebrikizumab for Idiopathic Pulmonary Fibrosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email


Lebrikizumab is an experimental drug aimed at treating inflammatory and fibrotic diseases. Owing to its immunosuppressive potential, it has been tested against diseases like asthma and refractory Hodgkin’s Lymphoma with successful results. Currently, the company is also pursuing studies to test its use in Idiopathic Pulmonary Fibrosis.

Lebrikizumab was first developed by Texas-based biopharmaceutical company Tanox under the name TNX-650. Genentech acquired Tanox in 2007 and initiated successful clinical trials, testing the therapy in refractory Hodgkin’s Lymphoma and asthma.


Read more about it: http://bit.ly/1l7hj1n

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums